Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Epizyme Announces Date of Fourth Quarter and Full Year 2017 Results Conference Call and Upcoming Presentation at the Cowen 38th Annual Health Care Conference

Posted on: 27 Feb 18

CAMBRIDGE, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will host a conference call in conjunction with the announcement of its fourth quarter and full-year 2017 financial results and present at the Cowen 38th Annual Health Care Conference. Details of both events are as follows:

  • Fourth Quarter and Full-Year 2017 Financial Results: Management will host a conference call and webcast to discuss its fourth quarter and full year 2017 financial results and other business highlights at 8:30 a.m. ET on Tuesday, March 13, 2018. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 7299537.

  • Cowen and Company 38th Annual Health Care Conference Presentation: Management will present a company overview at the Cowen 38th Annual Health Care Conference on Wednesday, March 14, 2018 at 9:20 a.m. ET in Boston.

Live webcasts will be available in the investor section of the company's website at The webcasts also will be archived for 60 days following the call and presentation.

About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy in relapsed and front-line disease. The company is also developing a novel G9a program and its next development candidate, EZM8266, is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme's science seeks to match targeted medicines with the patients who need them. For more information, visit


Cheya Pope, Epizyme, Inc.
(617) 229-7561

Jason Fredette, Epizyme, Inc. 
(617) 500-0623


Last updated on: 27/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.